Aclarion, Inc.

Aclarion operates as a healthcare technology company focused on spinal imaging and analysis. The company developed NOCISCAN, a diagnostic system that uses magnetic resonance spectroscopy (MRS) to non-invasively assess the chemical composition of intervertebral discs in the spine. NOCISCAN extends standard lumbar MRI examinations by applying proprietary biomarkers and analytical protocols to quantify degenerative markers within spinal tissue.

The company's product suite includes the NOCISCAN MRS Exam Protocol, a software protocol designed for use with commercially available MRI equipment, and a post-processing software platform. The NOCISCAN Post-Processor Suite comprises two components: NOCICALC, a Class I medical device that processes raw MRS data and calculates degenerative pain biomarkers, and NOCIGRAM, which converts those calculations into NOCISCORES on a 0-10 scale representing relative degenerative marker levels for each disc examined. Aclarion also offers AMBRA Healthcare, an imaging data transfer platform, and NOCIWEB, a custom web interface for accessing diagnostic information.

Based in Broomfield, Colorado, Aclarion operates with a minimal employee base of approximately five full-time staff members. The company was incorporated in Delaware in 2008 and changed its name from Nocimed, Inc. to Aclarion, Inc. in December 2021. The company is listed on Nasdaq.